Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(33%)

Phase Distribution

Ph not_applicable
3
50%
Ph phase_1
1
17%
Ph phase_3
1
17%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

2 of 6 finished

Non-Completion Rate

66.7%

4 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(2)
Terminated(4)

Detailed Status

Completed2
Terminated2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 31 (20.0%)
N/A3 (60.0%)

Trials by Status

completed233%
terminated233%
withdrawn233%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_3

Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency

NCT04231279
completed

Optical and Biochemical Biomarkers in Early Pancreatic Cancer

NCT03404661
completednot_applicable

Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients

NCT01094561
withdrawnnot_applicable

Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery

NCT01094535
terminatedphase_1

Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma

NCT00587132
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04231279Phase 3

Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency

Terminated
NCT03404661

Optical and Biochemical Biomarkers in Early Pancreatic Cancer

Completed
NCT01094561Not Applicable

Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients

Completed
NCT01094535Not Applicable

Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery

Withdrawn
NCT00587132Phase 1

Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma

Terminated
NCT01094600Not Applicable

Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6